Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103825 | 0.89 | MEN1 (0.39) | ITGB3ITGA2BHDAC8HDAC1REN | |
| SCHEMBL18103789 | 0.89 | MEN1 (0.39) | ITGB3ITGA2BHDAC8HDAC1REN | |
| Hydrochloric Acid SCHEMBL18103782 | 0.84 | GZMB (0.36) | F2REN | |
| Hydrochloric Acid SCHEMBL18103778 | 0.84 | GZMB (0.36) | F2REN | |
| SCHEMBL18103807 | 0.80 | ACE (0.42) | RENCTSDKLK7KLK5KMT2A | |
| SCHEMBL18103810 | 0.80 | ACE (0.42) | RENCTSDKLK7KLK5KMT2A | |
| SCHEMBL19180869 | 0.76 | GZMB (0.40) | RENCXCR3KMT2A | |
| SCHEMBL19182515 | 0.76 | GZMB (0.40) | RENCXCR3KMT2A | |
| SCHEMBL19182556 | 0.75 | GZMB (0.37) | HDAC8RENMEN1KMT2A | |
| SCHEMBL19182557 | 0.75 | GZMB (0.37) | HDAC8RENMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969772-B2 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458192-B1 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | ITGB3 514/4885ITGA2B 255/4885HDAC8 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.